Evidence map›Paper›PMID 34946766›Full record

ArticleMolecules (Basel, Switzerland)2021

Nanogold Particles Suppresses 5-Flurouracil-Induced Renal Injury: An Insight into the Modulation of Nrf-2 and Its Downstream Targets, HO-1 and γ-GCS.

Mohamed El-Sherbiny, Eslam K Fahmy, Nada H Eisa, Eman Said, Hany A Elkattawy, Hasnaa Ali Ebrahim, Nehal M Elsherbiny, Fatma M Ghoneim

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Unraveling the Potential ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  7. Sinapic acid alleviates 5-fluorouracil-induced nephrotoxicity in rats via Nrf2/HO-1 signalling.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Mohamed El-SherbinyDepartment of Basic Medical Sciences, College of Medicine, Almaarefa University, P.O. Box 71666, Riyadh 11597, Saudi Arabia.ORCID 0000-0002-0814-1743
Eslam K FahmyMedical Physiology Department, College of Medicine, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0002-1994-2570
Nada H EisaDepartment of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
Eman SaidDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0001-5529-6994
Hany A ElkattawyDepartment of Basic Medical Sciences, College of Medicine, Almaarefa University, P.O. Box 71666, Riyadh 11597, Saudi Arabia.ORCID 0000-0003-1701-9894
Hasnaa Ali EbrahimDepartment of Basic Medical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
Nehal M ElsherbinyDepartment of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0001-5167-3377
Fatma M GhoneimHistology and Cell Biology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mansoura University · EGAlfaisal University · SANorthern Border University · SAPrincess Nourah bint Abdulrahman University · SA

Funding

Princess Nourah bint Abdulrahman University PNURSP2022R171
6 · The paper itself

Abstract

The development of the field of nanotechnology has revolutionized various aspects in the fields of modern sciences. Nano-medicine is one of the primary fields for the application of nanotechnology techniques. The current study sheds light on the reno-protective impacts of gold nano-particles; nanogold (AuNPs) against 5-flurouracil (5-FU)-induced renal toxicity. Indeed, the use of 5-FU has been associated with kidney injury which greatly curbs its therapeutic application. In the current study, 5-FU injection was associated with a significant escalation in the indices of renal injury, i.e., creatinine and urea. Alongside this, histopathological and ultra-histopathological changes confirmed the onset of renal injury. Both gene and/or protein expression of nuclear factor erythroid 2-related factor 2 (Nrf-2) and downstream antioxidant enzymes revealed consistent paralleled anomalies. AuNPs administration induced a significant renal protection on functional, biochemical, and structural levels. Renal expression of the major sensor of the cellular oxidative status Nrf-2 escalated with a paralleled reduction in the renal expression of the other contributor to this axis, known as Kelch-like ECH-associated protein 1 (Keap-1). On the level of the effector downstream targets, heme oxygenase 1 (HO-1) and gamma-glutamylcysteine synthetase (γ-GCS) AuNPs significantly restored their gene and protein expression. Additionally, combination of AuNPs with 5-FU showed better cytotoxic effect on MCF-7 cells compared to monotreatments. Thus, it can be inferred that AuNPs conferred reno-protective impact against 5-FU with an evident modulatory impact on Nrf-2/Keap-1 and its downstream effectors, HO-1 and γ-GCS, suggesting its potential use in 5-FU regimens to improve its therapeutic outcomes and minimize its underlying nephrotoxicity.

Indexed as

AnimalsDisease Models, AnimalFluorouracilgamma-GlutamylcyclotransferaseGoldHeme Oxygenase (Decyclizing)Injections, IntraperitonealKidneyMetal NanoparticlesNanotechnologyNF-E2-Related Factor 2Particle SizeRatsRats, Sprague-DawleyFluorouracilgamma-GlutamylcyclotransferaseGoldHeme Oxygenase (Decyclizing)Hmox1 protein, ratNfe2l2 protein, ratNF-E2-Related Factor 25-flurouracilnanogoldNrf-2

Identifiers

PMID34946766
PMCPMC8707269
OpenAlexW4200250806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.